Condition: Pancreatic Ductal Adenocarcinoma (PDAC) · Sponsor: BicycleTx Limited
This is a Phase 2 study for nuzefatide pevedotin (BT5528) in adults with a specific type of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC) that has spread and worsened after one previous treatment. The drug, nuzefatide pevedotin (nuzefatide), is designed to find a specific protein called EphA2. The main aims of the study are to see how well the drug works against the tumor (efficacy), what side effects it may have (safety), and how the body processes it (pharmacokinetics). All participants in this study will receive nuzefatide, and both they and their doctors will know what is being administered (single-arm, open-label). The trial will take place at several different medical centers.
This description comes directly from the study's public registry record.
BicycleTx Limited · 6179458155 · clinicalstudies@bicycletx.com
Always discuss trial participation with your own doctor first.
| Siteman Cancer Center (Washington University School of Medicine) | St Louis, Missouri, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center - Main Campus | New York, New York, United States | Recruiting |
| Thomas Jefferson University, Sidney Kimmel Comprensive Cancer Center, Clinical Trials Office | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07450859